Jim Cramer Says Tariff Pain Isn’t Over Yet And Reviews These 9 Stocks

3. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 83

Johnson & Johnson (NYSE:JNJ) was portrayed as a fundamentally strong healthcare name dragged down by sentiment and litigation risk. Cramer acknowledged investor fears surrounding the talc lawsuits but suggested the worst-case scenario may be priced in. Here’s his analysis:

“Wow, J&J is another one people like that’s just going down so much. But a lot of people just are very fearful of Robert Kennedy Jr. […] For retail investors, there are these stocks that have good yield and good fundamentals. And I think that J&J is one of those. And Goldman recommends it today. And I just urge people to take a look and say, you know what, that stock is down, not down all the way at the bottom, but it’s very low. And maybe I should be a buyer. […]

[Talking about the talc litigation] I think the talc litigation, that was a very bad blow for them. That they were paying, say, ten. But I will tell you this, that if you just amortize how much they have to pay, even if it’s twelve, fifteen, or if you talk about them fighting, they haven’t lost any suits since the Missouri government. […] I do think that they’re going to come out okay on that.. But I am confident that they have, they can fight each one, it’ll cost money, but the plaintiffs should have, there’s just only one plaintiff that’s really holding out, so I like it.“